Zelená J, Hájek R
Laborator experimentálni hematologie a bunecné imunoterapie, Oddelení klinicke hematologie FN, Brno-Bohunice.
Cas Lek Cesk. 2007;146(7):586-92.
The understanding haematological malignancies at the protein level is important for the prediction of therapy response, the possibility for disease diagnostics, the development of targeted treatment, and it must be based on the knowledge regarding the molecular pathogenesis of the tumour. 'Proteomics' describes the analysis of the entire proteome of a cell or a tissue and incorporates multiple technologies, including - Western blotting, two-dimensional polyacrylamide gel electrophoresis, mass spectrometry, and ProteinChip-based technology. Although there is a limited number of studies to date in haematological malignancies, those performed highlight the potential impact of these technologies in the discovery of novel markers associated with the drug resistance and the identification of biomarkers which may facilitate the development of a rapid diagnostic test that would be easily applicable in the clinical setting. Thereby this article describes used proteomics techniques and highlights studies regarding proteomic research in haematological malignancies, namely the primarily publications concerning research of multiple myeloma, leukaemias and lymphomas.
在蛋白质水平上理解血液系统恶性肿瘤对于预测治疗反应、疾病诊断的可能性、靶向治疗的发展至关重要，并且必须基于有关肿瘤分子发病机制的知识。“蛋白质组学”描述了对细胞或组织的整个蛋白质组的分析，并结合了多种技术，包括蛋白质印迹法、二维聚丙烯酰胺凝胶电泳、质谱分析和基于蛋白质芯片的技术。尽管迄今为止关于血液系统恶性肿瘤的研究数量有限，但已进行的研究突出了这些技术在发现与耐药性相关的新标志物以及鉴定生物标志物方面的潜在影响，这些生物标志物可能有助于开发一种易于在临床环境中应用的快速诊断测试。因此，本文描述了所使用的蛋白质组学技术，并重点介绍了有关血液系统恶性肿瘤蛋白质组学研究的情况，即关于多发性骨髓瘤、白血病和淋巴瘤研究的主要出版物。
